Macquarie Group
OMED

Macquarie Group’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Macquarie Group’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-29,589
Closed -$22K – 2339
2018
Q4 		$22K Sell
29,589
-21,720
-42% -$32.7K ﹤0.01% 1779
2018
Q3 		$109K Sell
51,309
-29,127
-36% -$69.8K ﹤0.01% 1579
2018
Q2 		$186K Buy
+80,436
New +$234K ﹤0.01% 1684

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group's OMED Position: Q1 2019 in Review

Macquarie Group sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2019, closing a stake of 29,589 shares — an estimated $22K sold.

Macquarie Group first reported a position in OMED in Q2 2018 and held it in 3 quarters. The position peaked at $186K in Q2 2018. 41 funds tracked by Wall St. Rank hold OMED as of Q1 2019.

  • Macquarie Group reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 29,589 OncoMed Pharmaceuticals, Inc. shares in Q1 2019, an estimated $22K.
  • Macquarie Group first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2018 and held it in 3 quarters.
  • Macquarie Group's OncoMed Pharmaceuticals, Inc. position peaked at $186K in Q2 2018.
  • 41 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.